Tenax Therapeutics Inc (TENX) moved from Buy to Neutral at Chardan Capital on August 11, 2026, following a downgrade.
One of five firms active in the past 90 days rates the stock in the bullish tier. The consensus price targets from 10 analysts as of October 30, 2026, have a mean of $9.82, a median of $5.10 and a range of $4.04 to $36.75.
Consensus Q4 FY2026 EPS is -$0.36, with revenue at $0. The next earnings report is on March 8, 2027.
